EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY 4.0

Assessment of the efficacy and safety of two albendazole regimens for the treatment of hypermicrofilaraemic loiasis in adults in Woleu-Ntem Province, Gabon: A phase IIb single-blind randomised controlled trial

Noé Patrick M'Bondoukwé iD, Luccheri Ndong Akomezoghe, Bridy Chesly Moutombi Ditombi, Jacques Mari Ndong Ngomo, Hadry Roger Sibi Matotou, Ginette Severine Zang Ondo, Valentin Migueba, Coella Joyce Mihindou, Bedrich Pongui Ngondza, Christian Mayandza, Héléna Noéline Kono, Dimitri Ardin Moussavou Mabicka und 5 weitere

PLOS Neglected Tropical Diseases · 20.01.2026 · 20 (1) · e0013166

DOI: 10.1371/journal.pntd.0013166 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift PLOS Neglected Tropical Diseases, online erschienen am 20.01.2026. Verfasst von Noé Patrick M'Bondoukwé und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Parasitology-Mycology-Tropical Medicine, Faculty of Medicine, Université des Sciences de la Santé, Libreville, Gabon. Hauptthemen laut MEDLINE: Albendazole, Loiasis, Filaricides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European and Developing Countries Clinical Trials Partnership.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background Loa (L.) loa hypermicrofilaraemia (≥ 8,000 mf/mL) increases the risk of severe adverse events during mass ivermectin administration for onchocerciasis control. Albendazole has been proposed as a potential alternative for reducing microfilaraemia prior to ivermectin administration. Methodology and principal findings This prospective study was conducted in northern Gabon from November 2021 to April 2022. Individuals infected with L. loa were screened and allocated to three groups: two treatment arms receiving 400 mg or 800 mg of albendazole daily for 30 days among hypermicrofilaraemic participants, and a group with microfilaraemia < 8,000 mf/mL. Clinical symptoms and parasitological data were collected on Days 0, 2, 7, 14, and 30. A total of 70 participants were enrolled: 16 in the 400 mg group, 16 in the 800 mg group, and 38 in the group with microfilaraemia below 8,000 mf/mL. Itching was the most frequently reported adverse event. By Day 30, no participants in the group with microfilaraemia below 8,000 mf/mL presented with clinical symptoms. Microfilaraemia significantly decreased in all groups (p < 0.01). After 30 days, over 70.0% of patients treated with albendazole had microfilaraemia < 8,000 mf/mL. There was no significant difference in efficacy between the two albendazole regimens. Conclusions/Significance Daily administration of 400 mg albendazole for 30 days effectively reduces microfilarial loads in patients with L. loa hypermicrofilaraemia and is well tolerated and safe. This pre-treatment regimen may reduce the risk of adverse events associated with ivermectin administration. Further research is needed to evaluate the long-term persistence of microfilarial suppression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlbendazoleLoiasisFilaricidesHumansAdultMaleFemaleGabonMiddle AgedProspective StudiesAnimalsYoung AdultLoaTreatment OutcomeSingle-Blind MethodIvermectinAdolescent

Substanzen

AlbendazoleIvermectinFilaricides

Autor:innen und Institutionen

  • Department of Parasitology-Mycology-Tropical Medicine, Faculty of Medicine, Université des Sciences de la Santé, Libreville, Gabon.

ORCID-Profile: Noé Patrick M'Bondoukwé

Förderung

  • European and Developing Countries Clinical Trials Partnership

Zitieren

APA

M'Bondoukwé, N. P., Ndong Akomezoghe, L., Moutombi Ditombi, B. C., Ndong Ngomo, J. M., Sibi Matotou, H. R., Zang Ondo, G. S., Migueba, V., Mihindou, C. J., Pongui Ngondza, B., Mayandza, C., Kono, H. N., Moussavou Mabicka, D. A., Manomba, C., Moutongo, R., James, L. A. J., Mawili Mboumba, D. P., & Bouyou Akotet, M. K. (2026). Assessment of the efficacy and safety of two albendazole regimens for the treatment of hypermicrofilaraemic loiasis in adults in Woleu-Ntem Province, Gabon: A phase IIb single-blind randomised controlled trial. PLOS Neglected Tropical Diseases, 20(1), e0013166. https://doi.org/10.1371/journal.pntd.0013166

Vancouver

M'Bondoukwé NP, Ndong Akomezoghe L, Moutombi Ditombi BC, Ndong Ngomo JM, Sibi Matotou HR, Zang Ondo GS, et al. Assessment of the efficacy and safety of two albendazole regimens for the treatment of hypermicrofilaraemic loiasis in adults in Woleu-Ntem Province, Gabon: A phase IIb single-blind randomised controlled trial. PLOS Neglected Tropical Diseases. 2026;20(1):e0013166. doi:10.1371/journal.pntd.0013166

BibTeX
@article{MBondoukw2026,
  author = {M'Bondoukwé, Noé Patrick and Ndong Akomezoghe, Luccheri and Moutombi Ditombi, Bridy Chesly and Ndong Ngomo, Jacques Mari and Sibi Matotou, Hadry Roger and Zang Ondo, Ginette Severine and Migueba, Valentin and Mihindou, Coella Joyce and Pongui Ngondza, Bedrich and Mayandza, Christian and Kono, Héléna Noéline and Moussavou Mabicka, Dimitri Ardin and Manomba, Charleine and Moutongo, Reinne and James, Luice Aurtin Joel and Mawili Mboumba, Denise Patricia and Bouyou Akotet, Marielle Karine},
  title = {Assessment of the efficacy and safety of two albendazole regimens for the treatment of hypermicrofilaraemic loiasis in adults in Woleu-Ntem Province, Gabon: A phase IIb single-blind randomised controlled trial},
  journal = {PLOS Neglected Tropical Diseases},
  year = {2026},
  volume = {20},
  number = {1},
  pages = {e0013166},
  doi = {10.1371/journal.pntd.0013166}
}
Kostenlos starten →